OTC Deficiency clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 12 years and up
The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels with removal of dietary protein restriction and alternative pathway medication.
Los Angeles, California and other locations